VotedBy VotedBy ⌕
Election Day · Tue, Nov 3See how your members of Congress voted →

H.R. 4895 · 118th Congress

Lowering Drug Costs for American Families Act

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Never voted on. It didn't reach a floor vote before the 118th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.

FPD PalloneSponsor
74 cosponsors · 74 D
RND Neal BSD Scott SBD Bonamici DBD Beyer KCD Castor SCD Cohen JCD Courtney JCD Chu ACD Craig SCD Cherfilus-McCormick DED Evans LFD Frankel JGD Gomez RGD Garcia GID Ivey HJD Johnson WKD Keating RKD Kelly AKD Kim JLD Larson KMD Mfume BMD McCollum END Norton JRD Raskin JSD Schakowsky ESD Slotkin HSD Stevens MTD Thompson DTD Titus PTD Tonko DTD Trone SWD Wild RGD Grijalva DGD Goldman TLD Lieu GMD Meng JMD McClellan JSD Sarbanes GSD Sablan MTD Takano BBD Balint MDD DeSaulnier DDD Dingell KMD Manning GMD Moore JMD Morelle SMD Magaziner DWD Wasserman Schultz NBD Barragán DDD DeGette JPD Panetta YCD Caraveo ASD Salinas NWD Williams GCD Connolly VED Escobar DKD Kildee RLD Larsen KPD Porter SDD Davids CPD Pingree ASD Spanberger MCD Cartwright JND Nadler JTD Tokuda SLD Lee BLD Lee MKD Kaptur LSD Sánchez YCD Clarke LFD Fletcher BSD Sherman DMD Matsui GSD Stanton

2 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

This bill expands the Medicare Drug Price Negotiation Program to include additional drugs and drugs that are covered under private insurance. It also extends certain rebate requirements for covered drugs under Medicare to drugs that are covered under private insurance.

What it does: CRS summary · Introduced in House · Jul 26, 2023

Lowering Drug Costs for American Families Act

This bill expands the Medicare Drug Price Negotiation Program to include additional drugs and drugs that are covered under private insurance. It also extends certain rebate requirements for covered drugs under Medicare to drugs that are covered under private insurance.

Current law requires the Centers for Medicare & Medicaid Services (CMS) to negotiate maximum prices for brand-name drugs that do not have other generic equivalents and that account for the greatest Medicare spending; the CMS must eventually negotiate the prices of 20 drugs that are covered under Medicare in 2029 and each year thereafter.

The bill requires the CMS to negotiate the prices of 50 drugs beginning in 2029. It also applies the negotiated maximum prices under the program to drugs that are covered under private health insurance, unless the insurer opts out. The CMS, Department of Labor, and Department of Treasury must publish a list of insurers that choose to opt out; insurers must also publicly disclose their decision to opt out.

Current law also requires drug manufacturers to issue rebates to the CMS for brand-name drugs without generic equivalents under Medicare that cost $100 or more per year per individual and for which prices increase faster than inflation. The bill extends these requirements to drugs that are covered under private insurance.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: Lowering Drug Costs for American Families Act

Latest action (Dec 17, 2024): Referred to the Subcommittee on Health.

Policy area: Health · Origin: House · Introduced: Jul 26, 2023

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

No recorded floor vote found.